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Previously, we demonstrated that progesterone (P4) promoted adult rat neural progenitor cell
(rNPC) proliferation with concomitant regulation of cell-cycle gene expression via the P4 receptor
membrane component/ERK pathway. Here, we report the efficacy of seven clinically relevant
progestins alone or in combination with 17-estradiol (E2) on adult rNPC proliferation and hip-
pocampal cell viability in vitro and in vivo. In vitro analyses indicated that P4, norgestimate,
Nestorone, norethynodrel, norethindrone, and levonorgestrel (LNG) significantly increased in
rNPC proliferation, whereas norethindrone acetate was without effect, and medroxyprogesterone
acetate (MPA) inhibited rNPC proliferation. Proliferative progestins in vitro were also neuropro-
tective. Acute in vivo exposure to P4 and Nestorone significantly increased proliferating cell nuclear
antigen and cell division cycle 2 expression and total number of hippocampal 5-bromo-2-deoxyuri-
dine (BrdU)-positive cells, whereas LNG and MPA were without effect. Mechanistically, neurogenic
progestins required activation of MAPK to promote proliferation. P4, Nestorone, and LNG signif-
icantly increased ATP synthase subunit  (complex V, subunit ) expression, whereas MPA was
without effect. In combination with E2, P4, Nestorone, LNG, and MPA significantly increased BrdU
incorporation. However, BrdU incorporation induced by E2 plus LNG or MPA was paralleled by a
significant increase in apoptosis. A rise in Bax/Bcl-2 ratio paralleled apoptosis induced by LNG and
MPA. With the exception of P4, clinical progestins antagonized E2-induced rise in complex V,
subunit . These preclinical translational findings indicate that the neurogenic response to clinical
progestins varies dramatically. Progestin impact on the regenerative capacity of the brain has
clinical implications for contraceptive and hormone therapy formulations prescribed for pre- and
postmenopausal women. (Endocrinology 151: 5782–5794, 2010)
It is increasingly clear that gonadal hormone functionextends well beyond reproduction (1–3). In brain, pro-
gesterone (P4) exerts multiple nonreproductive functions
including regulating mood, inflammation, bioenergetics,
neural plasticity, cognition, and recovery from traumatic
brain injury (1, 2, 4–6). Clinically, P4 and related synthetic
progestins have been widely used as therapeutics for fer-
tility, contraception, and hormone replacement therapy
(1, 2, 7–10). The majority of progestins are derived from
three tetracyclic structures: pregnane, estrane, and gonane
and have varying degrees of specificity for P4 receptors
(PRs) (Fig. 1) (9, 10). Recently, a newer class of progestins,
the 19-norprogesterone molecules, has been developed
with improved progestational activity with little to no an-
drogenic activity and used for contraception and hormone
therapy (11).
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Although the effect of progestins on the reproductive
system has been extensively studied, their impact on cen-
tral nervous system function, particularly adult neurogen-
esis and cell viability, remains largely unexplored (1). The
generation of new neurons or neurogenesis in the two pro-
liferative zones of the brain, the subgranular zone of the
hippocampus and the subventricular zone of the cerebral
ventricles, is the principle regenerative strategy of the adult
brain. In parallel, cellular viability can be a predictive in-
dicator of the health of newly generated and existing cells.
In this study, we selected seven clinically relevant progestins
as representative of three different classes of progestins to
determinetheireffectsonneuralprogenitorproliferationand
neuronal viability (Fig. 1): one with pregnane structure [me-
droxyprogesterone acetate (MPA)], one with 19-norproges-
terone structure (Nestorone), three with estrane structure
[norethindrone (NET), NET acetate (NETA), and nore-
thynodrel], and two with gonane structure [levonorgestrel
(LNG) and norgestimate (NGM)]. Notably, NETA, nore-
thynodrel, and NGM are prodrugs; the first two require
in vivo conversion to NET to exert their progestational
effects, whereas the latter requires conversion to LNG
for activity (8, 12).
Analyses reported here were conducted to determine the
impact of clinically relevant progestins on the regenerative
capacityofbrainwhenadministeredaloneor incombination
with 17-estradiol (E2). Results of these
studies indicate that acute exposure to
clinically relevant progestins and E2/pro-
gestin combinations differentially regu-
lated neurogenic and neuroprotective re-
sponses in brain. The data indicate that
clinical progestins vary dramatically in
their impact, which can range from pro-
moting the regenerative function of the




drel, LNG, MPA, and NGM were purchased
from Steraloids (Newport, RI). Nestorone
was provided by Sitruk-Ware (Rockefeller
University and Population Council, New
York, NY).
PR, androgen receptor (AR), and
glucocorticoid receptor (GR)
competitive binding
The binding affinities of tested proges-
tins to PR, AR, and GR were determined by
fluorescent polarization competitive bind-
ing assays using purified baculovirus-ex-
pressed human PR/AR/GR and fluorescent P4/androgen/glu-
cocorticoid ligand PL Red (Invitrogen, Grand Island, NY) as
described before (7, 13), respectively. Polarization values were
determined using GENios Pro microplate reader (Tecan, San
Jose, CA) and plotted against the logarithm of the concentrations
of test compounds. IC50 values were determined by nonlinear
least-squares analysis.
Culture of rat neural progenitor cells (rNPCs)
Rat NPCs derived from adult rat dentate gyrus (gift from Fred
Gage; Laboratory of Genetics, The Salk Institute, CA) were pro-
vided as cryopreserved cells. They were cultured as described
previously (7, 13, 14) in DMEM/Hams F-12 medium (1:1;
Omega Scientific, Tarzana, CA) with 1% penicillin/streptomy-
cin/amphotericin B (Invitrogen), supplemented with N2 (1%;
Invitrogen) and basic fibroblast growth factor (bFGF) (20 ng/ml;
Invitrogen) in a humidified incubator (37 C and 5% CO2). Cells
were plated at a density of 2  e6 cells/flask or 7.5–15  e4
cells/well  96-well plates.
5-Bromo-2-deoxyuridine (BrdU) incorporation
Cell proliferation was determined by S phase incorporation of
BrdU. After 4–6 h of starvation (medium without supplements),
rNPCs were loaded with 10 M BrdU in the presence or absence
of bFGF and varying concentrations of P4 or test progestins in
unsupplemented maintenance medium for 1d. The rNPCs were
then processed as described previously (7, 14). After subtracting
the value of the blank (without BrdU loading), data were ana-
lyzed using a one-way ANOVA, followed by a Neuman-Keuls
post hoc test.
FIG. 1. Chemical structures of clinically relevant progestins. Progestins are derived from four
tetracyclic structures: 19-norprogesterone, pregnane, estrane, and gonane. Although all three
structures bear four rings, identified as A, B, C, and D, the estrane structure differs from the
pregnane structure by lacking the C-19 angular methyl radical between rings A and B.
Gonane structure lacks both the C-18 and C-19 angular methyl radicals and bears an ethyl
group between rings C and D at C-13. Removal of C-19 methyl radical and addition of C-13
ethyl radical significantly enhances the progestational activities. The seven representative
progestins were the 19-norprogesterone, Nestorone; the pregnane, MPA; the gonanes,
leveonorgestrel and NGM; and the estranes, NET, NETA, and norethynodrel.
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Primary neuronal culture
Hippocampal neuronal cultures were prepared as previously
described (13).
Glutamate exposure and neuronal viability
Hippocampal neuronal cultures grown on 96-well culture
plates for 7d in vitro were pretreated with vehicle alone or test
compounds, followed by exposure to 200 M glutamate as pre-
viously described (13). After glutamate exposure, cultures were
washed with N-2-hydroxyethylpiperazine-N-2-ethane sulfonic
acid-buffered saline solution and replaced with fresh NBM con-
taining the test compounds or combinations. Cultures were re-
turned to the incubator and incubated for 24 h before analysis of
neuronal viability using colorimetric lactate dehydrogenase
(LDH) release in the media.
Animals
Use of animals was approved by the Institutional Animal Care
and Use Committee at the University of Southern California
(Protocol No. 10911). Embryonic d-18 fetuses derived from
time-pregnant Sprague Dawley rats (Harlan, Indianapolis, IN)
were used to obtain primary neuronal cultures for in vitro ex-
periments. Ovariectomized (OVX) 3-month-old adult female
Sprague Dawley rats (Harlan) were used for in vivo experiments.
For progestin-only treatments (n  5 per group), rats were sc
injected 1 wk after ovariectomy with vehicle alone or P4 [30
g/kg body weight (BW)], Nestorone (30 g/kg BW), LNG (30
g/kg BW), and MPA (30 g/kg BW), respectively, and 1 h later
with 100 mg/kg BW BrdU injection. For E2 and progestin com-
bined treatments (n  5 per group), rats were sc injected 1 wk
after ovariectomy with either E2 alone (30 g/kg BW), or E2
combined with P4/Nestorone/LNG/MPA (30 g/kg BW), or
equivalent volume of sesame oil as vehicle control, respectively,
and 1 h later with 100 mg/kg BW BrdU injection. Doses of pro-
gestins were based on our previous in vivo studies, where the
same P4 treatment produced P4 levels in rats of 28 pg/g in brain
tissue and 20 pg/ml in serum (5). Animals were killed 24 h after
injection, and one hemisphere was fixed in 4% paraformalde-
hyde and processed for fluorescence-activated cell sorting
(FACS) analysis, and whole hippocampus (both posterior and
anterior hippocampus but not alveus or entorhinal/perirhinal
cortex) from the other hemispheres were manually dissected for
Western blot analysis.
Western blot analyses
Hippocampal samples from progestin-treated rats were as-
sessed for protein expression of proliferating cell nuclear antigen
(PCNA) (1:500; Zymed Laboratories, San Francisco, CA) and
cell division cycle 2 (CDC2) or cyclin dependent kinase 1 (Cdk1)
(1:500; Novus Biologicals, Littleton, CO), mitochondria com-
plex V, subunit  (CV) (1:1000; MitoSciences, Inc., Eugene,
OR), Bax (1:1000; Cell Signaling Technology, Danvers, MA),
and Bcl-2 (50E3) (1:1000; Cell Signaling Technology) by West-
ern blotting as previously described (7, 14). Relative amounts of
protein expression were quantified by optical density analysis
using UN-SCAN-IT gel automated digitizing system (Silk Scien-
tific, Inc., Orem, UT).
Nuclei extraction and flow cytometry counting
Hippocampi were dissected from the fixed hemispheres using
anatomical landmarks as described (15). Extracted hippocampi
were homogenized and nuclei sample collected into a 1.5 ml
microcentrifuge tube, washed four times using 200 l of PBS, and
then centrifuged for 10 min at 10,000 rpm. The pellet was then
resuspended in 600 l of PBS plus 0.5% Triton X-100, heated for
1 h at 75 C for epitope retrieval, and incubated for 24 h at 4 C
with primary mouse monoclonal anti-BrdU antibody (1:100,
Ab12219; Abcam, Cambridge, MA) for BrdU cell count or
with Clontech ApoAlert DNA Fragmentation Assay kit for DNA
fragmentation [terminal deoxynucleotidyltransferase-mediated
2-deoxyuridine 5-triphosphate nick end labeling (TUNEL)] de-
tection. The number of nuclei was estimated by counting the pro-
pidiumiodide,andthenumberofBrdUorTUNEL-labeledcellswas
detected using BD LSR II flow cytometer and BD FACSDiva soft-
ware (BD Biosciences, San Jose, CA).
Statistical analyses
Data are presented as mean  SEM and statistically significant
differences determined by a one-way ANOVA followed by a
Student-Newman-Keuls post hoc analysis.
Results
PR/GR/AR binding profiles of clinical progestins
To determine the binding profiles of tested progestins
(Fig. 1) to nuclear PR (nPR), fluorescence polarization-
based competitive binding assay was conducted (7, 13).
Competitive binding assays were also conducted to deter-
mine their binding affinities to AR and GR, respectively.
Data derived from the binding experiments are summa-
rized in Table 1. The binding IC50 values of P4, 9.01 nM for
PR, 119.3 nM for AR, and 6.51 nM for GR were consistent
with those reported previously (2). Among these proges-
tins, maximal binding affinity to nPR was exhibited by
Nestorone (IC50  5.07 nM), followed by LNG (IC50 
5.46 nM), MPA (IC50  6.20 nM), NET (IC50  14.32 nM),
NETA (IC50  38.92 nM), norethynodrel (IC50  67.76
nM), and NGM (IC50  482.80 nM). The low binding
affinities of NETA and NGM were consistent with their pro-
drugproperties,because theyrequireconversion toNETand
LNG, respectively, to exert progestational effects (11). With
respect to AR binding affinity, LNG exhibited maximal
binding affinity to AR (IC50  2.90 nM), followed by MPA
(IC50  4.53 nM), NGM (IC50  5.02 nM), NET (IC50 
18.02 nM), norethynodrel (IC50  196.70 nM), and NETA
(IC50  876.90 nM). Nestorone did not bind to AR, consis-
tentwithpreviousreports indicating thatNestoronehas little
androgenicactivity (16).Lastly,progestinbindingtoGRwas
as follows: MPA (IC50  1.42 nM), Nestorone (IC50  8.71
nM), LNG (IC50  16.73 nM), NET (IC50  97.84 nM),
NETA (IC50  202.70 nM), NGM (IC50  287.10 nM),
and norethynodrel (IC50  1306.00 nM). Overall, results
from these binding analysis confirmed previous reports
and provided a direct comparison of binding affinities of
tested progestins with PR, AR, and GR. Further, results
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indicated that clinical progestins have a complex binding
profile and have multiple targets in the biological systems
that are likely to impact outcomes in brain.
Clinical progestin regulation of rNPC proliferation
in vitro
Our previous study demonstrated that P4 increased
rNPC proliferation in a dose-dependent manner (7). To
determine whether progestins exhibited comparable effi-
cacy on rNPC proliferation, BrdU chemiluminescence
ELISA was conducted and compared with the proliferative
efficacy of P4 at the same concentration (Fig. 2). Results of
these analyses indicated that at 24 h, NGM was more
potent in promoting rNPC proliferation than P4 at all con-
centrations, with minimal effective dose of 1011 M and a
maximal effect of 40.4  1.5% increase at 109 M (P 
0.001). Nestorone and P4 were equally efficacious at their
EC100 concentrations, with both EC100 values being
1010 M. Norethynodrel induced a comparable effect with
P4 within the picomolar to low nanomolar range and was
significantly (P  0.005) more efficacious than P4 at high
nanomolar to micromolar range, with minimal effective
dose at 1011 M and maximal effective effect (43.5  3.7%
increase) at 107 M. NET induced a moderate effect in
promoting rNPC proliferation but was less effective than
P4 with a minimally effective dose of 10
11
M and a max-
imal effect was 21.8  1.7% increase at 106 M. Similarly,
LNG exhibited a minimally effective dose of 108 M and
a maximal effect of 17.7  0.8% at 107 M. NETA and
ORG 31710 exerted no effect on rNPC proliferation at all
concentrations except 105 M, a concentration at which
rNPC proliferation was significantly inhibited (P  0.05
and P  0.01, respectively). Lastly, MPA significantly in-
hibited rNPC proliferation at multiple concentrations
with maximal inhibition at 1010 M to 105 M with rNPC
proliferation reduced by 17.0  1.3% (P  0.05) and
17.8  1.2% (P  0.05), respectively.
Progestin-induced cell proliferation is dependent
on ERK signaling pathway and independent of
nPR
Previously we demonstrated that P4-induced cell pro-
liferation is an ERK signaling pathway-dependent process
(7). To determine whether ERK activation was required
for progestin-induced cell proliferation, BrdU chemilumi-
nescence ELISA was conducted in the presence or absence
of the MEK kinase inhibitor UO126 (Fig. 3A). Consistent
with results in Fig. 2, at 108 M, both P4 and Nestorone
significantly increased BrdU incorporation by 14.6 and
16.4% compared with vehicle control, respectively (P 
0.0001 and P  0.0001, respectively). At 108 M, LNG
had no statistically significant effect, although a positive
trend was observed, whereas MPA significantly inhibited
BrdU incorporation (P  0.05). Inhibition of ERK/MAPK
signaling pathway by UO126 abolished P4-induced cell
proliferation (P  0.0001), which replicated our previous
findings (7), and completely inhibited the proliferative ef-
fects of Nestorone and LNG (P  0.0001 and P  0.05,
respectively) with no effect observed on MPA-induced in-
hibition of cell proliferation. These data indicate that like
P4, Nestorone- induced, and LNG-induced cell prolifera-
tion require the ERK signaling pathway, whereas the in-
hibitory effect of MPA is independent of the ERK/MAPK
signaling pathway.
Analysis of the structure-activity relationship (SAR)
was conducted to determine structural molecular features
required for proliferative efficacy of clinical progestins.
The presence of an acetyl or hydroxyl group at the 17S-
position of the D ring was favorable for rNPC prolifera-
tion, whereas a methyl group at the 6-position, whether it
was in the R or S configuration, negatively impacted cell
proliferation (Fig. 3B). A modification at the 10R-position
or at the 13S-position had no effect on the proliferative
capabilities of the molecule nor did the position of the

















P4 9.01 100 6.51 119.30 4.78 87.72 0.05
MPA 6.20 145.30 1.42 4.53 0.23 0.73 0.31
Nestorone 5.07 177.70 8.71 NB 1.72 NA () NA ()
NET 14.32 62.90 97.84 18.02 6.83 1.26 5.43
NETA 38.92 23.20 202.70 876.90 5.21 22.53 0.23
Norethynodrel 67.76 13.30 1306.00 196.70 19.27 2.90 6.64
LNG 5.46 165.20 16.73 2.90 3.07 0.53 5.77
Norgestimate 482.80 1.87 287.10 5021.00 0.59 10.40 0.06
Fluorescence polarization-based competitive binding assays were conducted to determine the binding profile of test progestins to PR, GR, and AR.
IC
50
refers to the concentration of test progestins resulting in a half-maximal shift in polarization value, which was determined from the binding
curve by a nonlinear least-squares analysis. The relative binding affinity (RBA) of test progestins is expressed as percent of the binding affinity of
progesterone (RBA  100%). Selectivity was calculated as the ratio between the binding IC50. NA, Not applicable; NB, no binding.
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double bond between C-4 and C-5 or between C-5 and
C-10. Interestingly, addition of a hydroxyl group at the
C-17-position is known to eliminate the progestational
effect of progestins, whereas acetylation of the C-17-OH
can reverse this effect to render the progestins orally active.
Addition of the 13-C ethyl group is positively associated
with the highest progestational activity, consistent with
findings that helix 12 Met909 is the key residue for PR
activation by both testosterone- derived and P4-derived
progestins with a 13-methyl or a 13-ethyl substitutions
FIG. 2. Progestin regulation of NPC proliferation. Rat NPCs were starved for 4 h before exposure to clinical progestins (10  e12 to 10  e5 M)
for 24 h. Cell proliferation was evaluated by BrdU chemiluminescence ELISA measuring BrdU incorporation. Ethanol was used as vehicle control
(1  e6), and bFGF was used as positive control. At each concentration, the proliferative efficacies of progestins (solid lines) were compared
against that of P4 (dotted line). A–C, Effects of progestins that had greater proliferative efficacy relative to P4. D and E, Progestins with lower
proliferative efficacy relative to P4. F–H, Progestins with no or antagonizing effects on cell proliferation. Data are derived from three independent
assays, analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc test, and plotted as percentage increase vs. vehicle control (mean 
SEM). *, P  0.05; **, P  0.01; ***, P  0.005; and ****, P  0.001 vs. vehicle control.
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(17). Surprisingly, modifications favoring the prolifera-
tive effect of the progestins are negatively correlated with
their binding affinity to nPR. Thus, it is likely that the
proliferative effects of progestins are not mediated by nPR,
which is consistent with our previous finding that nPR
is not expressed in rNPCs, that the proliferative effect of
P4 in rNPCs is not mediated by nPR but is instead me-
diated by the membrane PR membrane component 1
(PGRMC-1) (7).
Clinical progestin regulation of neuroprotection
in vitro
Previous analyses indicated that P4 exerted significant
neuroprotection against neurodegenerative insults (5, 18).
We therefore determined whether clinical progestins exerted
comparableefficacy inprotectingprimaryhippocampalneu-
rons against degeneration induced by excitoxic glutamate.
LDH release in the culture medium served as an indicator of
neuronal membrane integrity, a minimum requirement for
neuroprotection (13). Dose-response analysis was con-
ducted for each progestin (Fig. 4) with neuroprotective effi-
ciency (NE) calculated as follows:
NE  (Vsample  Vglutamate)/(Vcontrol  Vglutamate)
Consistent with previous findings (5, 18), P4 induced a
significant (P  0.05) protective effect with a minimally
effective concentration of 1011 M and maximal effect of
55.7  13.3% at 107 M. Nestorone induced comparable
neuroprotective efficacy with that of P4, with a minimally
effective concentration of 1011 M and a maximal effect of
57.0  4.4% at 107 M. Norethynodrel was more potent
than P4, and its minimal effective concentration was
1011 M, a concentration at which it also exhibited max-
imal neuroprotection of 80.8  1.8% (P  0.001). LNG
induced comparable efficacy with P4, with a minimally
effective concentration 1011 M, a concentration at which
LNG also induced maximal neuroprotection of 39.6 
3.2% (P  0.001). In contrast, NGM was much less potent
with neuroprotection at 107 M, whereas both MPA and
NET showed modest neuroprotection at 1011 M but were
without effect at other concentrations. Similar to the re-
sults of clinical progestin regulation of rNPCs prolifera-
tion, no association was found between the neuroprotec-
tive efficacy of the progestins and their binding affinities to
PR, AR, or GR.
Clinical progestins regulate neurogenic activity
and cell viability in vivo
To determine the generalizability of in vitro findings to
the in vivo condition, analyses of rNPC proliferation and
cell viability were conducted in 3-month-old Sprague
Dawley OVX female rats treated with selected progestins.
Selection of progestins for in vivo testing was based on the
requirement that the progestin exert both a significant in-
crease in rNPC proliferation and neuroprotection. Among
these progestins, Nestorone, norethynodrel, and LNG ful-
filled these criteria. However, norethynodrel was not ad-
vanced to in vivo testing because of its aromatization in
liver to form the potent estrogen ethinyl-estradiol (19) and
thus potential involvement of ER in proliferative action in
vivo could not be excluded. Although MPA exerted a de-
crease in both rNPC proliferation and neuroprotection, it
was included for in vivo analysis based on its continued
clinical use and its controversial effects in brain (5, 20, 21).
In addition to FACS determination of total number of
BrdU hippocampal cells, two cell cycle protein markers,
PCNA, which is associated with transition through S
phase, and CDC2 (CDK1), which is associated with tran-
sition through the mitotic M phase, were assessed (7, 14).
Results of cell cycle protein expression as determined by
Western blotting indicated that both P4 and Nestorone
FIG. 3. Progestin-induced cell proliferation is dependent on MAPK
and independent of cPR. A, BrdU chemiluminescence ELISA was
carried out to determine the signaling cascade of progestin-induced
cell proliferation. Rat NPCs were starved for 4 h before exposure to
100 pM progestin alone or progestin combined with MAPK inhibitor
UO126 (100 nM) for 24 h, and cell proliferation was evaluated by BrdU
chemiluminescence ELISA measuring BrdU incorporation. Ethanol 
DMSO (1  e6) was used as vehicle control, and bFGF was used as
positive control. Data were collected from four independent assays,
analyzed using one-way ANOVA, followed by Neuman-Keuls post hoc
test, and plotted as percentage increase vs. vehicle control (mean 
SEM). *, P  0.05; **, P  0.01; ***, P  0.005; and ****, P 
0.0001 vs. vehicle control; †, P  0.05; ††††, P  0.001 vs. progestin-
alone group. B, Structure-activity analysis of progestin-induced
proliferative effects. Critical structural features of progestins required
for proliferative effects from SAR analysis.
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significantly increased PCNA expression at the protein
level (P  0.05 and P  0.01, respectively) (Fig. 5A),
whereas LNG and MPA had no significant effect upon
PCNA protein expression (P  0.15 and P  0.08, re-
spectively) (Fig. 5A, top). CDC2 protein expression was
significantly increased by P4 and Nestorone (P  0.05 and
P  0.01, respectively), whereas LNG and MPA had no
significant effect on CDC2 protein expression (P  0.07
and P  0.23, respectively) (Fig. 5A, bottom).
To assess the total number of BrdU cells, the con-
tralateral hippocampal hemisphere used for protein anal-
ysis was fixed and processed for FACS analysis. Total
number of BrdU cells per each hippocampus was deter-
mined and normalized to that of vehicle control. Results
were plotted as the percent increase in BrdU cell ratio
compared with vehicle control (Fig. 5B). Results derived
from FACS analysis indicated that P4 and Nestorone sig-
nificantly increased BrdU cell number (P  0.05 and P 
0.01, respectively), whereas LNG induced a comparable
increase in BrdU incorporation with P4 but was not sta-
tistically significant (P  0.054). Further, MPA, which
inhibited rNPC proliferation in vitro, had no significant
effect on rNPC proliferation in vivo. Results of FACS anal-
yses are consistent with data derived from Western blot
analyses.
Previous analyses demonstrated that P4 increased cell
viability by promoting mitochondrial function and reduc-
ing oxidative damage (4). As a marker of cell viability,
FIG. 4. Neuroprotective efficacy of clinical progestins. Rat primary hippocampal neurons were exposed to neurotoxic glutamate 200 M and the
protective effects of progestins determined by LDH release. The neuroprotective effect was defined as NE and calculated as follows: NE  (Vsample 
Vglutamate)/(Vcontrol  Vglutamate). Data are presented as the percentage of values produced by vehicle-treated control cultures, and the proliferative efficacy
of each progestin (solid line) was compared with that of P4 (dotted line). A–C, Progestins with neuroprotective efficacy comparable with P4. D–F, Clinical
progestins with modest neuroprotective efficacy. *, P  0.05; **, P  0.01; ***, P  0.005; and ****, P  0.001 compared with glutamate-treated
cultures.
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expression of the -subunit of ATP synthase-complex V
(CV) of the mitochondrial oxidative phosphorylation
pathway was assessed by Western blot analysis. Consis-
tent with previous results (4), P4 significantly increased
CV expression in vivo by 1- to 2-fold (P  0.05) (Fig. 5C).
Nestorone and LNG also significantly increased CV ex-
pression in vivo (P  0.01 and P  0.05 compared with
vehicle control, respectively) (Fig. 5C), whereas MPA ex-
FIG. 5. Progestin regulation of neurogenic and neuroprotective activity in the hippocampus of OVX adult female rat. P4, Nestorone, LNG, and
MPA were selected for in vivo efficacy assessment for their regulation of neurogenic activity; 30 g/kg BW progestins were injected to 3-month-
old OVX female rat followed by BrdU injection 1 h later. A, Effect of tested progestins on cell proliferation marker PCNA and CDK1 protein level in
the hippocampus. B, Progestin regulation of BrdU cell count in the hippocampus of OVX adult female rat. *, P  0.05 and **, P  0.01
compared with vehicle control. C, left, Effects of progestins on CV expression in rat hippocampus at protein level. Right, Effects of progestins on
Bax/Bcl-2 expression ratio at protein level. P  0.05 and P  0.08, respectively.
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erted no significant effect on CV expression level, al-
though a trend toward a decrease was observed (P  0.18).
One of the closely associated events of increased cell
viability is decreased apoptosis. To determine the effects of
progestins on apoptosis, Western blot analyses were con-
ducted to determine the expression level of Bax, a medi-
ator of apoptosis by translocating to the mitochondria to
release apoptotic factors such as cytochrome c (22), and
Bcl-2, an antiapoptotic protein that is a key component of
the neuroprotective effect of E2 (22). Ratio of Bax to Bcl-2
was used as the indicator of in vivo apoptotic activity,
because it positively correlates with apoptosis. P4 and
Nestorone had no effect on the ratio of Bax/Bcl-2 ex-
pression, whereas LNG (P  0.05) and MPA (P  0.05)
significantly increased Bax/Bcl-2 ratio consistent with
its proapoptotic effect in uterus reported by other groups
(23–25). Together with previous results on CV expres-
sion, the in vitro neuroprotective efficacy of clinical pro-
gestins paralleled their efficacy in vivo to induce markers
of cell viability.
Impact of clinical progestins in combination with
E2 on neurogenesis and cell viability in vivo
When used clinically for hormone replacement therapy/
contraceptive therapy, progestins are administered in con-
junction with an estrogen. To determine the impact of the
combination of E2 and clinical progestins on neurogenesis
and cell viability in vivo, young adult OVX female Sprague
Dawley rats were divided into six groups and received sc
injection with either E2 alone (30 g/kg BW) or E2 com-
bined with either P4, Nestorone, LNG, MPA (30 g/kg
BW), or equivalent volume of sesame oil as vehicle con-
trol. Hippocampi were isolated 24 h later for Western
blot analysis and flow cytometry to determine the im-
pact of treatment on cell viability and neurogenesis,
respectively.
Expression level of PCNA, which is associated with
transition through S phase, was assessed to determine the
impact of treatment groups on the entry into the cell cycle
required for neurogenesis. Results of these analyses indi-
cated that E2 significantly increased PCNA expression at
the protein level, and combination of E2 and progestins
were progestin dependent (Fig. 6A): E2Nestorone in-
duced the greatest magnitude of PCNA expression (P 
0.01), whereas E2P4, E2LNG and E2MPA exhibited
comparable increase in PCNA level (P  0.05). Further,
E2Nestorone-induced PCNA expression was signifi-
cantly greater when compared with E2 alone (P  0.05).
Entry into the cell cycle was confirmed by FACS analysis,
which detected BrdU incorporation in the contralateral
hippocampal hemisphere (Fig. 6B). Consistent with
PCNA expression, E2 and its combination with progestins
significantly increased the BrdU cell population. In con-
trast to the effect of MPA in vitro, where MPA inhibited
rNPC proliferation, and in vivo, where it had no effect on
PCNA expression or BrdU incorporation as detected by
FACS, the E2MPA group exhibited the greatest increase
in the number of BrdU cells indicated by a significant
4-fold increase compared with vehicle control (P  0.01)
and a 1-fold increase when compared with that of E2-alone
group (P  0.05). Because neither LNG nor MPA induced
a rise in PCNA, CDC2, or BrdU incorporation when ad-
ministered in the absence of E2, we determined whether
the rise in BrdU induced by these progestins in the presence
of E2 was associated with an increase in apoptosis.
To address this issue, analysis of cell viability and ap-
optosis were conducted. Indicators of cell viability were
expression of mitochondrial ATP synthase subunit CV
expression and Bax/Bcl-2 ratio (Fig. 6, C and D). Consis-
tent with previous analyses, E2 increased cell viability by
promoting mitochondrial function and reducing oxida-
tive damage (26), E2 significantly increased CV protein
expression relative to vehicle control (Fig. 6C). E2P4 sig-
nificantly increased CV expression comparable with that
of E2-alone group, whereas E2Nestorone and E2LNG
significantly decreased CV protein expression relative to
E2 alone. Remarkably, E2MPA significantly reduced
CV expression below that expressed in response to either
vehicle or E2 (P  0.05 and P  0.01, respectively) (Fig.
6C). In parallel, E2 significantly decreased the apoptosis
indicator Bax/Bcl-2 ratio, whereas E2Nestorone, or
LNG or MPA, increased the Bax/Bcl-2 ratio relative to E2
alone, although the increase did not exceed the vehicle
(Fig. 6D). These results are consistent with previous re-
ports from our group and others indicating a lack of syn-
ergy in the neuroprotective effects when P4 and E2 were
administered in combination (18, 27) and that MPA could
inhibit E2-induced neuroprotective effect by antagonizing
E2-induced attenuation of intracellular calcium concen-
tration (5, 18, 21).
The rise in the Bax/Bcl2 ratio relative to E2 suggested
the potential of an apoptotic effect. To determine whether
a rise in apoptosis paralleled the rise in Bax/Bcl2 ratio,
TUNEL labeling was performed to identify apoptotic nu-
clei in response to different treatments of E2 and progestins
(Fig. 6E), and TUNEL cell numbers were detected via
flow cytometry analysis. Results of the FACS analysis in-
dicated that treatment with either E2 alone, E2P4, or
E2Nestorone had no effect on TUNEL cell number
relative to vehicle-treated animals. In contrast, E2LNG
induced a 4- and a 2-fold increase in the number of
TUNEL cells relative to vehicle and E2-alone group, re-
spectively (P  0.01 and P  0.05). The magnitude of
TUNEL cells was maximal in the hippocampi derived
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from E2MPA-treated animals. E2MPA-treated ani-
mals exhibited an 8- and a 4-fold increase in TUNEL cell
count relative to vehicle and E2-alone group, respectively
(P  0.01 and P  0.01). This is consistent with the pro-
apoptotic effect of LNG and MPA in the uterus (23–25).
Collectively, these data indicate that clinical progestins
can exert significantly different outcomes on the survival
of proliferating NPCs in vivo.
FIG. 6. Combined effect of E2 and progestin on neurogenic activity and apoptosis in vivo. Vehicle, 30 g/kg BW E2, and 30 g/kg BW progestins
combined with 30 g/kg BW E2 were injected to 3-month-old OVX female rat followed by BrdU injection 1 h later. A, Effects of E2 and E2  progestins
on PCNA expression level in hippocampus. B, Combined effect of E2  progestin in regulating BrdU cell count in the hippocampus of OVX adult female
rat. *, P  0.05 and **, P  0.01 compared with vehicle control; †, P  0.05 compared with E2-alone group. C, Effects of E2 and E2  progestins on
CV expression at protein level. Western blot analysis was conducted on protein isolated from hippocampus. D, Effects of E2 and E2  progestins on Bax/
Bcl-2 expression at protein level. E, Combined effect of E2  progestin in regulating TUNEL cell count in the hippocampus of OVX adult female rat.
*, P  0.05 and **, P  0.01 compared with vehicle control; †, P  0.05 and ††, P  0.01 compared with E2 group.
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Discussion
In the present study, we conducted comparative analyses of
seven clinically relevant progestins to determine their neu-
rogenic and neuroprotective efficacy both in vitro and in
vivo, as well as their efficacy in regulating neurogenesis and
cell viability in vivo when coadministered with E2. Results of
these analyses indicated that clinical progestins exert a range
of effects that span promotion of neurogenesis and neuro-
protection to inducing apoptosis and reduced cell viability.
P4, the endogenous regulator of P4 action promoted neuro-
genesis and neuroprotection served as the comparator pos-
itive control. Four of the seven clinical progestins exerted an
increase of rNPC proliferation in vitro and were also neuro-
protective. In vivo analyses indicated that when adminis-
tered alone, P4 and the clinical progestin Nestorone signifi-
cantly increased rNPC proliferation; and Nestorone and
LNGincreasedCV expressionwithanefficacycomparable
with or greater than P4. MPA was without effect in both
neurogenesis and cell viability measurements. When coad-
ministeredwithE2,P4,Nestorone,LNG,andMPAincreased
entry into cell cycle, whereas LNG and MPA increased ap-
optosis in parallel. The induction of apoptosis by LNG and
MPA is consistent with their antagonism of E2-induced in-
crease in CV expression and decrease in Bax/Bcl-2 ratio.
As an initial comparative approach for the in vivo exper-
iments, we used comparable doses of all progestins based on
an effective dose of P4 to induce rNPC proliferation in vivo.
The dose of P4 used in this study translates into a concen-
tration of 20 pg/ml in serum (21), comparable with that of P4
in woman’s brain during follicle phase but much lower than
luteal phase (10–30 ng/ml) or pregnancy (50 ng/ml). Thus
theeffectsofprogestinsat the testedconcentrationarewithin
clinically relevant range. However, uterine bioassays of the
progestational activity of these progestins in uterus indicate
substantially different dose response profiles (8, 12). Further
analyses are required to investigate the impact of compara-
tively equivalent doses of the progestins based on their pro-
gestational potency in human uterus.
Progestin regulation of neurogenic activity and
cell viability in vitro and in vivo
A major finding of our analysis was that similar to P4,
progestins can regulate rNPC proliferation in a dose-depen-
dent manner. Among the seven progestins tested, NGM,
Nestorone, norethynodrel, NET, and LNG increased BrdU
incorporation comparable with that of P4, NETA exhibited
no effect on rNPC proliferation, whereas MPA significantly
inhibited rNPC proliferation. Further, the prodrugs nore-
thynodrel and NGM were significantly more potent than
their active metabolites, NET and LNG, respectively, indi-
cating that conversion to active metabolites and binding to
nPR were not required for their in vitro proliferative action.
Consistent with our previous findings (7), proliferation
induced by clinical progestins was dependent on the ERK
signaling pathway and independent of nPR binding affin-
ity as evidenced by further SAR analysis. Interestingly,
MPA-induced inhibition of cell proliferation was not de-
pendent on MAPK/ERK signaling pathway, because co-
administration of UO126 had no impact on MPA-induced
inhibition. This could be explained by our previous find-
ing that MPA-induced pERK is not translocated to the
nucleus (18, 28), indicating that signaling pathways other
than the ERK may mediate the inhibitory effect of MPA.
A likely PR candidate for mediating rNPC proliferation is
the membrane-associated PGRMC-1. Our previous report
demonstrated that P4 significantly increased rNPC prolifer-
ation in a PGRMC-1 and MAPK-dependent manner (7).
SAR analysis highlighted several critical structures for their
proliferative efficacy of clinical progestins, and those struc-
tural features revealed no clear association with other bind-
ing affinity to nPR. The lack of an effect of the pure nPR
agonistORG31710supports thepostulate thatnPRwasnot
the mediator of the proliferative effect of progestins. It is
possible, however, that the proliferative effects of the pro-
gestins were combined effects of binding to multiple recep-
tors rather than one. Indeed, as reported herein and by oth-
ers, LNG and NGM exerts androgenic effects by binding to
and activating the nuclear AR. However, NGM in contrast
with LNG inhibited nuclear translocation of the AR, reveal-
ing an antiandrogenic property (29). Also norethynodrel in-
duces estrogenic activity through aromatization in vivo. Al-
though Nestorone can bind to the nuclear GR, it showed no
glucocorticoid activity in vivo (16, 30, 31). In addition, nPR
is expressed in the dentate gyrus of hippocampus, and acti-
vation of nPR by P4 is known to inhibit cell proliferation
under various conditions (1). Further, the effects of proges-
tinsonglialcellpopulationandpotentialglial-neuronalcross
talk remained undetermined.
An increase in neural responses induced by selected
progestins was also evident in vivo. Consistent with their
in vitro proliferative effects, P4 and Nestorone signifi-
cantly increased cell cycle protein expression and BrdU
cell number in FACS analyses compared with vehicle-
treated animals. The profile for LNG was consistent in
that LNG failed to increase PCNA/CDC2 expression or
total BrdU cell number as determined by FACS analysis.
Although the lineage of the newly generated cells remains
to be determined, these data provide preclinical evidence
that clinically relevant progestins could significantly im-
pact the regenerative capability of the brain.
The in vitro and in vivo neuroprotective effect of P4 has
been reported by multiple groups (2, 4, 5, 20). Results from
the current analyses extend these findings to now include
up-regulationofakeymarkerofmitochondrial functionand
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cell viability in vivo. Further, our results demonstrate that
clinically relevant progestins can differentially regulate neu-
ron survival and viability. In vitro, norethynodrel, Nestor-
one, and LNG protected rat primary hippocampal neurons
against glutamate-induced toxicity, whereas NGM, NET,
and MPA exerted no significant effect. The lack of neuro-
protective capability of MPA is consistent with our previous
report (18, 32). In vivo analyses confirmed that P4, Nestor-
one, and LNG induced a significant rise in CV expression,
whereas MPA showed no effect, indicating the neuroprotec-
tive effects of the progestins are closely related to their ability
in regulating mitochondria function. In addition, only LNG
and MPA significantly increased Bax/Bcl-2 ratio, which is
consistent with previous report that P4 does not directly reg-
ulate apoptosis, whereas both LNG and MPA induce a pro-
apoptotic effect in the uterus (23–25).
Combined E2 and clinical progestin regulation of
neurogenic activity and cell viability
It is well documented that E2 promotes neurogenesis and
protection against neurodegenerative insults (33). Reported
here, 30 g/kg BW E2 significantly increased both PCNA
expressionlevelandBrdUcellnumberatamagnitudecom-
parable with that of P4 alone. No significant differences were
observed between E2-alone, E2P4, and E2Nestorone
group.This is incontrastwithpreviousreports fromTanapat
et al. (27), where P4 administration subsequent to estradiol
exposure decreased the amplitude of E2-induced increase in
BrdU cell count. However, this could be explained by the
differences in the treatment paradigm; Tanapat et al. (27)
used chronic E2 exposure followed by P4 administration,
whereas in our study, E2 and P4 treatment administration
was acute and simultaneous. Further, there was no syn-
ergy in E2P4-induced response compared with E2 or P4
alone. This is consistent with our previous report of a
lack of synergy when P4 and E2 were administered in
combination (18, 28).
Both LNG and MPA increased BrdU cell count when
administered in combination with E2. However, in paral-
lel to the increase in BrdU cells, LNG and MPA signif-
icantly increased the number of TUNEL cells indicative
of increased apoptosis, which is consistent with the pro-
apoptotic effects of LNG and MPA in the uterus (23, 24).
Although the phenotype of the apoptotic cells remains
unidentified at this point, it is probable that the increase of
TUNEL cell population reflects the premature death of
the newly generated cells (BrdU cells).
Therapeutic implications of progestin regulation of
neural proliferation and viability
Clinical progestins are an integral constituent of oral con-
traceptive therapy, progestin-only contraception, fertility
therapy, and postmenopausal hormone therapies. Progestin
containing contraceptives account for an increasing propor-
tion of modern contraceptive formulations used by women
around the world. In the United Kingdom, the progestins
mainly used are 19-nortestosterone derivatives (NETA, nor-
gestrel, and LNG) (8, 34). In France, micronized P4 and 19-
norprogesterone (suchaspromegestoneandnomegestrolac-
etate) are commonly prescribed, whereas MPA is the most
prescribed progestin in the United States and the progestin
used in commonly randomized controlled hormone therapy
trials including the Women’s Health Initiative (35) and
Women’s Health Initiative Memory Study (36). Typically,
clinical progestins are chronically administered extending
overmanyyears todecades.For example,depomedroxypro-
gesterone acetate, a long-acting formulation of MPA, is ex-
tensively prescribed for adolescent females (37), and Nor-
plant implant delivers constant infusion of LNG for 5–7 yr
(38). Although data contained herein are derived from acute
in vitro and in vivo exposures, our emergent findings suggest
thatchronicusecouldhave long-termimplications forneural
function, regenerative capacity, and viability. Although the
impact of chronic exposure to clinical progestins remains
undetermined, the acute in vivo data indicate that P4 and
Nestorone have potential beneficial outcomes for inducing
andsustainingregenerativecapacityof thebrain. Incontrast,
LNG and MPA could have potential adverse outcomes on
regenerative capacity of the brain.
Collectively, results of these preclinical translational
analyses indicate that clinical progestins vary dramatically
in their impact on the regenerative capacity of the brain
and thus are likely to have clinical implications for long-
term neurological function.
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